Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2139 USD | -0.49% | +7.43% | -83.16% |
04-23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call | |
04-01 | CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 6.67M 9.1M |
---|---|---|---|---|---|
Net income 2022 | -15M -20.48M | Net income 2023 | -18M -24.57M | EV / Sales 2022 | - |
Net cash position 2022 | 9.65M 13.17M | Net cash position 2023 | 248K 338K | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.21
x | P/E ratio 2023 |
-0.25
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.47% |
Latest transcript on CNS Pharmaceuticals, Inc.
1 day | -1.40% | ||
1 week | +7.43% | ||
Current month | -40.91% | ||
1 month | -40.55% | ||
3 months | -35.53% | ||
6 months | -89.36% | ||
Current year | -83.16% |
Managers | Title | Age | Since |
---|---|---|---|
John Climaco
CEO | Chief Executive Officer | 55 | 17-08-31 |
Director of Finance/CFO | 45 | 19-11-12 | |
Sandra Silberman
CTO | Chief Tech/Sci/R&D Officer | 69 | 17-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Picker
CTO | Chief Tech/Sci/R&D Officer | 78 | 17-12-31 |
John Climaco
CEO | Chief Executive Officer | 55 | 17-08-31 |
Faith Charles
CHM | Chairman | 62 | 23-01-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.2139 | -0.49% | 19 464 |
24-04-26 | 0.215 | +5.39% | 109,097 |
24-04-25 | 0.204 | -4.67% | 105,007 |
24-04-24 | 0.214 | +1.90% | 78,498 |
24-04-23 | 0.21 | +5.47% | 147,832 |
Delayed Quote Nasdaq, April 29, 2024 at 11:28 am
More quotes1st Jan change | Capi. | |
---|---|---|
-83.16% | 2.29M | |
+2.17% | 42.75B | |
+47.64% | 41.61B | |
+12.22% | 41.34B | |
-12.36% | 26.59B | |
+8.35% | 25.49B | |
-23.10% | 18.12B | |
+30.34% | 12.24B | |
-1.34% | 11.76B | |
+8.43% | 11B |
- Stock Market
- Equities
- CNSP Stock